2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). (September 2015) - Abad, A.; Massuti, B.; Gravalos, C.; Escudero, P; Guillen-Ponce, C.; Manzano, J.L.; Ortiz, M.J.; Safont, M.J.; Gallego, J.; Sastre, J.; Pericay, C.; Duenas, R.; et al.